Abstract
Purpose
Of more than one million global cases of breast cancer diagnosed each year, a high percentage are characterized as triple-negative, lacking the oestrogen, progesterone and Her2/neu receptors. The incidence exceeds the incidence of malignancies like CML by far. Lack of effective therapies, younger age at onset and early metastatic spread have contributed to the poor prognosis and outcomes associated with these malignancies.
Methods
Here, we investigate the ability of the PI3K/AKT inhibitor AEZS 126 to selectively target the triple-negative breast cancer (TNBC) cell proliferation and survival in vitro by MTT-assays and FACS-based analysis. Furthermore, the mechanism of cytotoxicity is analysed by FACS-based assays and Western blots.
Results
AEZS 126 showed good anti-tumour activity in in vitro models of TNBC as well as in MCF-7 cells. Main mechanism of cytotoxicity seems to be programmed cell death after an incubation time of 72 h, which could be abrogated by co-incubation with z-VAD-fmk in MCF-7 and MDA-MB468 cells. In HCC1806 cells, addition of necrostatin-1 has only slightly protective effects, but in HCC1937 cells, the addition of necrostatin-1 has the same protective effect as co-incubation with z-VAD-fmk, and this observation argues for cell death caused by apoptosis and necroptosis in this cell line.
Conclusion
We demonstrated the highly efficient anti-tumour activity of AEZS 126 in in vitro models of TNBC. Due to the good anti-tumour activity and the expected favourable toxicity profile, AEZS 126 in combination with chemotherapy seems to be a promising candidate for clinical testing in TNBC especially in the basal-like subgroup of TNBC.
Similar content being viewed by others
References
Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology 22:1233–1243
Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001–1012
Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728
Boucher D, Blais V, Denault JB (2012) Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis. PNAS 109:5669–5674
Bröker LE, Huisman C, Simone W et al (2004) Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 64:27–30
Campling BG, Pym J, Galbraith PR et al (1988) Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. Leuk Res 12:823–831
Candé C, Cecconi F, Dessen P et al (2002) Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? J Cell Sci 115:4727–4734
Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334
Chautan M, Chazal G, Cecconi F et al (1999) Interdigital cell death can occur through a necrotic and caspase-independent pathway. Curr Biol 9:967–970
Christofferson DE, Yuan J (2010) Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22:263–268
Degterev A, Huang Z, Boyce M et al (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1:112–119
Degterev A, Hitomi J, Germscheid M et al (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4:313–321
Dent R, Trudeau M, Pritchard KI et al (2007) Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434
Engel JB, Martens T, Hahne JC et al (2012) Effects of Lobaplatin as single agent and in combination with TRAIL on the growth of triple negative p53 mutated breast cancers in vitro. Anticancer Drugs 23:426–436
Frasci G, Comella P, Rinaldo M et al (2009) Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 20:1185–1192
Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657
Hahne JC, Honig A, Meyer SR et al (2012) Downregulation of AKT reverses platinum resistance of human breast cancers in vitro. Oncol Rep 28:2023–2028
Han J, Zhong CQ, Zhang DW (2011) Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nat Immunol 12:1143–1149
Jänicke RU, Ng P, Sprengart ML et al (1998a) Caspase-3 is required for α-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 273:15540–15545
Jänicke RU, Sprengart ML, Wati MR et al (1998b) Caspase-3 Is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273:9357–9360
Kennedy RD, Quinn JE, Mullan PB et al (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659–1668
Kroemer G, Galluzzi L, Vandenabeele P et al (2009) Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ 16:3–11
Lehmann BD, Bauer JA, Chen X et al (2011) Pietenpol. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767
Leist M, Jäättelä M (2001) Four death and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 8:589–598
Leong CO, Vidnovic N, DeYoung MP et al (2007) The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117:1370–1380
Li LY, Luo X, Wang X (2001) Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412:95–99
Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638–2645
Makin G, Hickman JA (2000) Apoptosis and cancer chemotherapy. Cell Tissue Res 301:143–152
Miao B, Degterev A (2009) Methods to analyze cellular necroptosis. Methods Mol Biol 559:79–93
Morris GJ, Naidu S, Topham AK et al (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer 110:876–884
Moulder SL (2010) Does the PI3 K pathway play a role in basal breast cancer? Clin Breast Cancer 3:66–71
Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125:627–636
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41:40–47
Rakha EA, El-Sayed ME, Green AR et al (2007) Prognosticmarkers in triple-negative breast cancer. Cancer 109:25–32
Rozman-Pungercar J, Kopitar-Jerala N, Bogyo M et al (2003) Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity. Cell Death Differ 10:881–888
Sirohi B, Arnedos M, Popat S et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19:1847–1852
Slee EA, Adrain C, Martin SJ (2001) Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276:7320–7326
Tischkowitz M, Brunet JS, Begin LR et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134
Torrisi R, Balduzzi A, Ghisini R et al (2008) Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 62:667–672
Tsujimoto Y (2003) Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Phys 195:158–167
Vandenabeele P, Galluzzi L, van den Berghe T et al (2010) Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 11:700–714
Xuan Y, Hu X (2009) Naturally-occurring shikonin analogues—a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett 274:233–242
Yang XH, Sladek TL, Liu X et al (2001) Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 61:348–354
Yuan J, Kroemer G (2010) Alternative cell death mechanisms in development and beyond. Genes Dev 24:2592–25602
Zheng TS, Hunot S, Kuida K et al (2000) Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nat Med 6:1241–1247
Acknowledgments
We appreciate the permission to use the INTAS ChemoStar Imager (Department of Microbiology, University of Würzburg). Therefore, we thank especially Prof. Rudel and Dr. Bergmann. This work was supported by a grant from IZKF (Interdiziplinäres Zentrum für Klinische Forschung; University of Würzburg).
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hahne, J.C., Schmidt, H., Meyer, S.R. et al. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer. J Cancer Res Clin Oncol 139, 905–914 (2013). https://doi.org/10.1007/s00432-013-1399-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-013-1399-z